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MaAortic stenosis represents a growing health care burden in high-income countries. Currently, the only deﬁnitive treatment
is surgical or transcatheter valve intervention at the end stages of disease. As the understanding of the underlying
pathophysiology evolves, many promising therapies are being investigated. These seek to both slow disease progression
in the valve and delay the transition from hypertrophy to heart failure in the myocardium, with the ultimate aim of
avoiding the need for valve replacement in the elderly patients afﬂicted by this condition. Noninvasive imaging has played
a pivotal role in enhancing our understanding of the complex pathophysiology underlying aortic stenosis, as well as
disease progression in both the valve and myocardium. In this review, the authors discuss the means by which contem-
porary imaging may be used to assess disease progression and how these approaches may be utilized, both in clinical
practice and research trials exploring the clinical efﬁcacy of novel therapies. (J Am Coll Cardiol Img 2019;12:185–97)
© 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).A ortic stenosis (AS) affects over 7 million peo-ple over 75 years of age in Europe and NorthAmerica, and its prevalence is expected to
triple in the next 40 years (1–3). The development of
effective medical therapy is a major unmet clinical
need that will require both a greater understanding
of the underlying pathophysiology and the adoption
of novel imaging methods to establish the safety
and efﬁcacy of candidate drugs. AS is a ﬁbrocalciﬁc
disease in which deposition of lipid, collagen, and
calciﬁcation leads to thickening and immobility of
the aortic valve leaﬂets, resulting in progressive valve
narrowing and obstruction to left ventricular outﬂow.
Over time, the left ventricle (LV) responds to the
consequent increase in afterload by myocyteN 1936-878X
m the aBritish Heart Foundation Centre for Cardiovascular Science, Un
gdom; bNational Heart and Lung Institute, Imperial College London, L
dicine, Québec Heart and Lung Institute, Laval University, Québec City,
/17/19/33226). Dr. Dweck is supported by the BHF (FS/14/78/31020) and
medical Research 2015 (15/JTA). The authors have reported that they ha
per to disclose.
nuscript received July 11, 2018; revised manuscript received October 10,hypertrophy, extracellular expansion, and ultimately
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review, we will discuss how these complex patho-
physiological processes might be monitored with
modern imaging techniques and ultimately modu-
lated using novel therapeutic interventions.
PATHOPHYSIOLOGY OF AS
THE VALVE. The initiation phase of AS shares many
pathophysiological similarities with atherosclerosis
and is dominated by inﬂammation, lipid inﬁltration,
and extracellular matrix remodeling under the con-
trol of inﬂammatory signaling pathways (6–10). Like
atherosclerosis, the initiating insult appears to be ahttps://doi.org/10.1016/j.jcmg.2018.10.023
iversity of Edinburgh, Edinburgh, Scotland, United
ondon, United Kingdom; and the cDepartment of
Québec, Canada. Dr. Doris is supported by the BHF
is the recipient of the Sir Jules Thorn Award for
ve no relationships relevant to the contents of this
2018, accepted October 18, 2018.
ABBR EV I A T I ON S
AND ACRONYMS
AS = aortic stenosis
AU = arbitrary unit(s)
AVA = aortic valve area
CMR = cardiac magnetic
resonance
CT = computed tomography
CT-AVC = computed
tomography aortic valve
calciﬁcation
ECV = extracellular volume
18F-NaF = radiolabeled sodium
ﬂuoride
ICC = intraclass correlation
coefﬁcient
LGE = late gadolinium
enhancement
Lp(a) = lipoprotein A
LV = left ventricle
MGP = matrix Gla protein
PET = positron emission
tomography
RANKL = receptor activator of
nuclear factor kappa-B ligand
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186combination of increased mechanical and
oxidative stress or reduced shear stress
leading to endothelial damage and a power-
ful inﬂammatory response. As this process
continues, inﬂammatory signaling pathways
are superseded by a powerful and relentless
cycle of progressive calciﬁcation, coordi-
nated by osteoblast-like cells and governed
by pro-osteogenic signaling pathways
(4,11,12). The accumulation of calcium within
the valve during the later propagation phase
induces further injury, thereby establishing a
vicious cycle of accelerating calciﬁcation and
progressive valvular obstruction.
THE MYOCARDIUM. In addition to progres-
sive valvular obstruction, AS has direct ef-
fects on the LV. Progressive valve obstruction
results in an increased afterload, triggering
myocyte hypertrophy and compensatory wall
thickening that initially preserves wall stress
and maintains cardiac output. Over time,
however, cellular hypertrophy progresses
to myocyte death, expansion of the extra-
cellular space, and replacement ﬁbrosis
(5,13–16). Indeed myocyte death andmyocardial ﬁbrosis drive LV decompensation and the
transition from hypertrophy to heart failure.
WHAT DO WE REQUIRE OF IMAGING IN AS?
Cardiac imaging is pivotal to the management of AS
and is relied on to conﬁrm the diagnosis and to grade
stenosis severity and assess myocardial health both at
baseline and over time. AS is a slowly progressive
condition that advances at a variable and inconsistent
rate. To accurately measure or predict disease pro-
gression over time, imaging tests must have sufﬁcient
reproducibility and robustness to detect small
changes in disease severity with high accuracy. In the
clinical setting, this is of utmost importance when
selecting the appropriate management strategy and
optimal timing of intervention for the individual pa-
tient. In the research setting, these attributes are
crucial in clinical trials seeking to investigate efﬁcacy
of novel therapies. Indeed, imaging biomarkers
with improved repeatability and sensitivity to change
will minimize sample sizes, follow-up duration,
and the expense of trials. Drug trials using imaging
endpoints therefore desire biomarkers that maximize
the progression-to-noise ratio: the ratio between
the magnitudes of average progression in a particular
parameter compared with its scan-rescan repeat-
ability (the error in measuring that parameter
on 2 different scans). Although transthoracicechocardiography has remained the gold standard
method for assessing the aortic valve and myocar-
dium and the tool of choice in the clinical setting,
novel imaging techniques demonstrate potential ad-
vantages and are therefore being increasingly
explored, particularly in clinical trials of novel ther-
apies (Central Illustration).
ASSESSING THE VALVE
ECHOCARDIOGRAPHY. While there may not be a true
reference standard for AS severity, echocardiography
is considered the gold standard for clinical assess-
ment. Early work in the 1970s found that Doppler
ultrasound could be used to examine the jets of ste-
notic and regurgitant lesions (17). This laid the
groundwork for Hatle et al. (18,19) to demonstrate
that Doppler ultrasound was highly feasible in AS and
the peak jet velocity, converted into a gradient using
the simpliﬁed Bernoulli equation (20), had good
agreement with invasive measurements. Otto et al.
(21), along with many other groups, have since
demonstrated that echocardiographic biomarkers
strongly predict the need for intervention. Finally,
the use of echocardiographic markers of severity as
enrolment criteria in the PARTNER B (Placement of
Aortic Transcatheter Valve) trial (22) demonstrates
the ability of echocardiography to select patients for
beneﬁcial therapy. Combined with the absence of
radiation, widespread availability, and low imaging
costs, these characteristics place echocardiography as
the ﬁrst-line modality for screening and serial follow-
up in AS.
Although multiple echocardiographic parameters
exist to assess disease severity, current guidelines
recommend the assessment of severity and progres-
sion based on peak velocity, mean gradient, and
aortic valve area (AVA) (23). Each of these central
parameters have been found to predict outcome
across multiple studies (24–26). Aortic peak velocity
remains the ﬁrst-line biomarker in the European So-
ciety of Cardiology/European Association for Cardio-
Thoracic Surgery 2017 guidelines, providing
powerful prognostic information and superior repro-
ducibility than other parameters (27,28). However,
peak velocity is dependent on ﬂow status and accu-
rate alignment of the echocardiography probe with
the jet of blood through the valve. Whereas mean
gradient is subject to the same limitations as peak
velocity, AVA is in principle less ﬂow-dependent.
However, measurements of AVA can represent an
important source of discrepancy, particularly as a
result of variations in direct measurements of the LV
outﬂow tract. As LV outﬂow tract diameter is squared
CENTRAL ILLUSTRATION The Role of Imaging in AS Progression
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Noninvasive imaging provides the ability to directly image the aortic valve and consequent pathophysiological effects on the myocardium. Imaging the valve may be
performed by computed tomography (CT) to quantify aortic valve calciﬁcation (AVC) load (CT-AVC), positron emission tomography (PET) to measure calciﬁcation
activity and/or echocardiography to assess hemodynamic severity. The response of the left ventricle (LV) may be assessed by echocardiographic measures of mass,
ejection fraction and/or strain, whereas cardiac magnetic resonance (CMR) offers additional quantiﬁcation of ﬁbrosis. The ability of these techniques to detect
therapeutic efﬁcacy depends on the scan-rescan repeatability of the test and the rate of change of the parameter being measured. These attributes are being
exploited in a number of ongoing studies to investigate novel therapies for aortic stenosis. AS ¼ aortic stenosis; ECV ¼ extracellular volume; iECV ¼ indexed
extracellular volume; LGE ¼ late gadolinium enhancement; PDE5 ¼ phosphodiesterase type 5.
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187to provide AVA by the continuity equation, small
differences in measurement can lead to signiﬁcant
variation and often to an underestimation of AVA.
Echocardiographic measurements therefore display
considerable variability, potentially leading to inac-
curacies when estimating disease progression. More-
over, echocardiographic measurements demonstrate
relatively slow progression with time. As a conse-
quence, the progression-to-noise ratio for most
echocardiographic assessments is not favorable
(29,30). Although this is often not a major issue in
clinical practice, in the research setting it means that
clinical trials require relatively large numbers of pa-
tients and prolonged follow-up to detect true treat-
ment effects (29).
An additional limitation worth considering is that
echocardiographic measures of AS often provideconﬂicting assessments of disease severity. Indeed,
discordant echocardiographic results are seen in one-
quarter of patients, most often arising from a valve
area <1 cm2, suggesting severe disease, and a peak
velocity <4.0 m/s or mean gradient <40 mm Hg,
indicating moderate stenosis (31,32). In cases of low-
ﬂow, low-gradient AS, ﬂow can be temporarily
increased to assess the true hemodynamic severity of
aortic valve disease. Low-dose dobutamine stress
echocardiography is often useful in this regard—with
an increase in velocity with increased ﬂow rates used
to diagnose true severe AS (33) and to discriminate
patients with and without contractile reserve (34).
However, a signiﬁcant proportion of patients with
discordant ﬁndings are in fact found to have normal
ﬂow status, making echocardiographic results difﬁ-
cult to interpret.
FIGURE 1 CT Calcium Scoring of the Aortic Valve
Patient A
CT-AVC 192 AU
Patient B
CT-AVC 3170 AU
An example of mild aortic valve calciﬁcation (AVC) (Patient A, top) and severe calciﬁcation by computed tomography (CT) (Patient B, bottom)
in axial (left) and short-axis (right) views of the valve. AU ¼ arbitrary unit(s).
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188For these reasons, interest in developing novel
assessments of disease severity and progression in AS
is growing, and novel imaging techniques may com-
plement echocardiography in adjudicating disease
severity and monitoring disease progression.
COMPUTED TOMOGRAPHY
CALCIUM SCORING
Calciﬁcation is the predominant process causing
valve obstruction in AS. Quantiﬁcation of the calcium
burden has therefore been suggested as an alternative
ﬂow-independent method of determining disease
severity (35). This was ﬁrst demonstrated using a
semiquantitative assessment on echocardiography
(35,36), although the clinical utility of this approach
has been limited by subjectivity and suboptimal
reproducibility (37). Interest has instead turned to
computed tomography (CT) calcium scoring, an
established clinical technique already widely used to
quantify coronary arterial calciﬁcation. Using anoncontrast, electrocardiography-gated CT acquisi-
tion and similar protocols as for coronary calcium
scoring, the burden of valvular calcium can be quan-
tiﬁed using the Agatston method, which encompasses
both the area and weighted density of a given region
of calciﬁcation (Figure 1).
Early studies of computed tomography aortic valve
calciﬁcation (CT-AVC) scoring highlighted that this
could provide a complementary measure of stenosis
severity, correlating moderately with hemodynamic
severity on echocardiography (37,38). A major
advance was the realization that men and women
require different calcium scores to develop severe
stenosis, even when adjusted for body size or LV
outﬂow dimensions, and therefore that sex-speciﬁc
thresholds were needed to grade severity (39). In
646 patients with normal LV systolic function, the
application of calcium score thresholds of 2,065
(arbitrary units [AU]) for men and 1,274 (AU) for
women correctly classiﬁed severe AS with a sensi-
tivity of $86% and speciﬁcity of $79% (31). These
FIGURE 2 18F-NaF PET-CT of the Aortic Valve
2.2
1.7
1.2
Contrast-enhanced computed tomography (CT) of the aortic valve (top) with fused radiolabeled sodium ﬂuoride (18F-NaF) positron emission
tomography (PET)–CT angiography images in the same patient (bottom). Strong PET uptake can be localized to the aortic valve in short-axis
(left), coronal (middle), and sagittal (right) views.
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189thresholds have been validated in a further multi-
center cohort of over 900 patients, holding particular
potential in adjudicating disease severity in patients
with discordant echocardiography results (32).
In addition to deﬁning severity, CT-AVC offers
powerful prediction of future clinical events. Indeed
in recent multicenter studies, severe calciﬁcation was
associated with a 3- to 4-fold increase in death or AVR
(32,40), emerging as an independent predictor of
these events after adjustment for clinical and echo-
cardiographic parameters. CT-AVC may also provide
value in measuring disease progression, improving
the progression-to-noise ratio previously discussed.
Quantiﬁcation of calcium by CT has been shown to
demonstrate excellent interobserver reproducibility
and scan-rescan repeatability; with limits of agree-
ment approximately 70 AU and variation of
approximately 4% to 8%, respectively (37,39,41).
Moreover, mean annual progression in calcium score
is relatively large, ranging from approximately 141
AU/year in mild AS to 361 AU/year in severe AS.
Whether CT calcium scoring will be modiﬁable with
medical therapies is yet to be determined; however,
its attributes have led to its adoption in the research
setting as the primary efﬁcacy endpoint in multiple
ongoing studies investigating novel treatments for
AS. CT calcium scoring is not currently recommended
for routinely tracking disease progression in theclinical arena, although recent European Society of
Cardiology guidelines support its use in adjudicating
disease severity in patients with discordant echocar-
diographic assessments and normal ﬂow (23).
POSITRON EMISSION TOMOGRAPHY
Positron emission tomography (PET) is another novel
technique, the use of which is being explored in AS.
By monitoring biological processes within the body,
this modality has the potential to offer important
mechanistic insights into pathophysiology. Further-
more, as a marker of disease activity and very early
calcium formation, there is growing interest in using
PET to detect early therapeutic effects in AS at a stage
in the process when calcium is more likely to be
reversible (Figure 2).
Radiolabeled sodium ﬂuoride (18F-NaF) is a widely
available PET tracer that can be used to measure
calciﬁcation activity in the vasculature, with an af-
ﬁnity for developing microcalciﬁcation (42–45).
18F-NaF activity is increased in patients with aortic
valve disease compared with the healthy population,
with a progressive rise in PET uptake with increasing
severity of AS (jet velocity and calcium score) (39).
Furthermore, early studies have suggested that
18F-NaF activity predicts the rate of future disease
progression as measured by CT-AVC and
FIGURE 3 18F-NaF PET-CT Predicts Disease Progression in AS
A — Patient  1
B — Patient  2
Baseline CT calcium score scans (left) for patients 1 (A) and 2 (B). Fused 18F-NAF PET-CT scans (middle) show ﬂuoride uptake in red and
yellow. Follow-up CT at 1 year (right) suggests that the baseline PET signal predicts where new macroscopic calcium, visible on the CT, is
going to develop. Reproduced with permission from Dweck et al. (45). AS ¼ aortic stenosis; other abbreviations as in Figures 1 and 2.
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190echocardiography (45,46). Indeed, new areas of
macrocalciﬁcation appear to subsequently develop at
sites of increased baseline 18F-NaF uptake, consistent
with this tracer identifying developing calciﬁcation
before it is visible on CT (Figure 3). As a marker of
disease activity, 18F-NaF therefore holds potential in
detecting therapeutic effects more rapidly than con-
ventional anatomical imaging approaches do (47).
Encouragingly, excellent reproducibility of this
technique has been demonstrated (intraclass corre-
lation coefﬁcient [ICC]: >0.8), and scan-rescan
reproducibility has also shown good agreement with
a percentage error of 10% (47). However, the incre-
mental value of this modality beyond anatomical
imaging modalities has yet to be shown and given the
cost, availability of scanners, and radiation exposure,
it is unlikely to be used clinically in the near future.
However, 18F-NaF PET does hold promise in the
research arena and as an endpoint in clinical trials of
novel therapy, potentially being more sensitive to
treatment effects than other imaging markers.
Although it remains to be determined whether the
aortic valve 18F-NaF PET signal is modiﬁable with
medical therapy, the same is true for all imaging
biomarkers in the absence of an effective medicaltherapy for this condition. Interestingly, skeletal
18F-NaF uptake in metabolic bone disease does
appear to be modiﬁable, demonstrating clear changes
after only 1 month of bisphosphonate therapy (48).
Another widely used PET tracer that has been
explored in imaging of the aortic valve is ﬂuo-
rodeoxyglucose F 18. This glucose analogue becomes
trapped in metabolically active cells and serves as a
surrogate marker for macrophage burden and
inﬂammation. In aortic stenosis, ﬂuorodeoxyglucose
F 18 activity is increased in patients with AS although
in practice image interpretation is frequently chal-
lenging due to overspill of activity from the adjacent
myocardium (39,45). Finally, the development of
PET–magnetic resonance imaging scanning platforms
provides new opportunities to perform PET imaging
studies at low radiation dose and potentially allowing
multiple time points to be studied in individual pa-
tients (49).
ASSESSING THE MYOCARDIUM
In addition to monitoring progressive valve narrow-
ing, noninvasive imaging may also provide detailed
assessments of the LV remodeling response: from
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191identifying initial compensatory hypertrophy to
tracking subsequent decompensation with the
development of progressive myocardial ﬁbrosis and
functional impairment. Such markers of LV decom-
pensation (e.g., inappropriate increases in LV mass,
high-sensitivity troponin levels, markers of myocar-
dial ﬁbrosis, global longitudinal strain, ejection frac-
tion) are consistently associated with an adverse
long-term prognosis in AS independent of disease
severity, underlying the importance of myocardial
health in this condition (50–52).
ECHOCARDIOGRAPHY. Echocardiography can pro-
vide assessments of LV mass and ejection fraction
that are adequate for routine clinical use and are
widely used for decision making. However, assess-
ments of LV mass by echocardiography demonstrate
poor reproducibility and scan-rescan repeatability
with variability in measurements of between 20 and
40 g (29). Indeed, this variability far exceeds the rate
of progression of LV mass (approximately 3 g/m2 per
year), meaning that echocardiography is not well
suited as an endpoint in research trials, mandating
extremely large sample sizes and prolonged follow-
up to detect even quite large treatment effects
(29,53).
Although echocardiography cannot directly assess
myocardial ﬁbrosis, surrogate markers provide in-
sights into the functional consequences of this
ﬁbrosis. Ejection fraction is widely measured in clin-
ical practice with reductions <50% an indication for
aortic valve replacement. However, this measure only
changes late in the disease process, also relies on
geometric assumptions, and is often confounded in
AS due to the presence of coexistent LV hypertrophy
(29). Global longitudinal strain measures myocardial
deformation by speckle tracking and, in asymptom-
atic patients with severe aortic stenosis, GLS may
provide prognostic information while ejection frac-
tion remains in the normal range (54,55). Further
work is required, however, to deﬁne relevant
thresholds to aid decision making and the ability of
GLS to track disease progression with time.
CARDIAC MAGNETIC RESONANCE. Cardiac magnetic
resonance (CMR) imaging, compared with echocardi-
ography, offers important advantages in the quanti-
ﬁcation of LV mass and ejection fraction. Excellent
intra- and interobserver as well as interstudy
repeatability have led to CMR becoming the gold
standard for this purpose (56–58). Indeed, the inter-
scan, interobserver, and intraobserver variability for
CMR assessments of LV mass have each been docu-
mented as <10 g (56,58). CMR therefore holds ad-
vantages in monitoring myocardial remodeling,potentially detecting even modest changes in
response to therapy. This was highlighted by the RIAS
(Ramipril in Aortic Stenosis) trial, which enrolled 100
patients with AS and demonstrated a subtle but sta-
tistically signiﬁcant reduction in LV mass after 1 year
in patients treated with ramipril (4 g) versus a
similar increase in LV mass (þ4.5 g) in the placebo
group (59).
Another major advantage of CMR is its ability to
provide noninvasive myocardial tissue characteriza-
tion using late gadolinium enhancement (LGE) and T1
mapping techniques (Figure 4). Gadolinium has been
widely used as an extracellular CMR contrast agent,
potently shortening tissue T1 values following intra-
venous administration. Altered kinetics in areas of
extracellular expansion can be exploited using
inversion recovery LGE sequences. By manually
setting the inversion time to “null” normal myocar-
dium, these areas appear black. Conversely, areas of
replacement ﬁbrosis are characterized by accumula-
tion and delayed washout of gadolinium, thereby
appearing white and facilitating the visualization of
myocardial scarring. In AS, replacement ﬁbrosis oc-
curs in a characteristic mid-wall pattern and can be
detected in 29% to 62% of patients (52,60,61).
Replacement ﬁbrosis may be quantiﬁed using semi-
automated techniques that are reproducible between
observers (ICC: >0.9; coefﬁcient of reproducibility: 16
mm2) (62,63). Once present, replacement ﬁbrosis ap-
pears to accumulate rapidly, increasing by up to 78%
per year (53), and both its presence and increasing
burden are strong predictors of adverse outcome
(52,61,64). Although progression may be halted by
aortic valve intervention, once present, replacement
ﬁbrosis appears to be irreversible (53,64,65). The
presence of mid-wall LGE has therefore been sug-
gested as an objective marker of LV decompensation
that can be used to optimize the timing of valve
intervention. Indeed this strategy is currently being
tested in the ongoing EVOLVED (Early Valve
Replacement Guided by Biomarkers of LV Decom-
pensation in Asymptomatic Patients With Severe AS)
randomized controlled trial (NCT03094143).
Myocardial ﬁbrosis may also be present in a diffuse
interstitial pattern, which is not detected by LGE
techniques. Instead, this process may be identiﬁed
and quantiﬁed using T1 mapping techniques that es-
timate absolute T1 values in a voxel-by-voxel map.
Native T1 values are raised in patients with severe AS
compared with healthy volunteers (66) and provide
prognostic information (67). However, there is sig-
niﬁcant overlap in native T1 values between patients
and healthy volunteers, between different sequences,
and between different magnetic ﬁeld strengths,
FIGURE 4 Myocardial Mass Quantiﬁcation and Tissue Characterization by CMR
2.2
A B
C D
Endocardial and epicardial contours can be accurately contoured to provide quantiﬁcation of left ventricular mass (A). Midwall ﬁbrosis on
delayed enhancement imaging (red arrow) (B). Native T1 map (C) and extracellular volume fraction map (D). CMR ¼ cardiac magnetic
resonance.
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192which have thus far limited its widespread applica-
tion. Whereas reproducibility of native T1 values is
excellent between observers (ICC: 0.99), repeatability
is more variable with an ICC of 0.72 for scan-rescan
measurements (68).
T1 mapping can also be repeated following admin-
istration of gadolinium, which enables calculation of
the extracellular volume fraction (ECV%) (i.e., the
fraction of the myocardial volume that is extracellular
space). This measure has been well validated against
collagen volume fraction on histology (69–71) as a
surrogate of diffuse ﬁbrosis and can also discriminate
between healthy volunteers and patients (68),
although again with signiﬁcant overlap. Measure-
ments of ECV fraction have been found to be highly
reproducible between observers and serial scans (ICC:
0.97 and 0.96, respectively) (68,70). An advantage is
that ECV fraction removes much of the variation
attributed to sequence and magnetic ﬁeld strength, sovalues are potentially comparable between centers.
However, more recent data have demonstrated that
balanced increases in both cellular hypertrophy and
ECV occur as the remodeling response progresses,
and that the ECV fraction appears to increase, not
decrease as one might expect, following AVR (due to
more rapid myocyte than ﬁbrosis regression). ECV
fraction would therefore appear to have limitations as
a method of tracking myocardial ﬁbrosis burden with
time or in tracking response to therapy (53). The
indexed ECV (iECV) is an alternative yet related
parameter that acts as a surrogate of the total
myocardial ﬁbrosis burden. It is calculated by multi-
plying the ECV fraction by the indexed volume of the
myocardium and may better reﬂect temporal changes
in the total burden of diffuse ﬁbrosis (51) (Figure 5). In
addition, indexed ECV appears clearly reversible
following valve replacement (53,72) and may offer
improved differentiation between disease states.
FIGURE 5 Changes in LVMi, Diffuse Fibrosis (iECV), and Replacement Fibrosis (LGE) in AS Before and After AVR
4.9V max (m/s)
Patient A
Patient B
Increasing aortic stenosis severity with time
Baseline 1 year
Baseline 1 year
148LVMi (g/m2)
iECV (mL/m2)
5.0LGE (g)
42.0
5.4
151
13.8
48.4
5.3V max (m/s)
116LVMi (g/m2)
iECV (mL/m2)
2.6LGE (g)
31.9
2.9
94
3.3
23.6
AVR
In Patient A, new areas of late gadolinium enhancement (LGE) are seen on follow-up (red arrow). In Patient B, following aortic valve replacement (AVR), both cellular
hypertrophy and the total myocardial ﬁbrosis burden (iECV) regress. By comparison, replacement ﬁbrosis appear irreversible (white arrow). Reproduced with
permission from Everett et al. (53). AS ¼ aortic stenosis; iECV ¼ indexed extracellular volume; LVMi ¼ left ventricular mass index; Vmax ¼ peak aortic-jet velocity.
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193Indexed ECV is therefore potentially the most
attractive measure for assessing myocardial ﬁbrosis
progression in AS, with further multicenter trials
required for validation.
USE OF IMAGING TO TEST DRUG EFFICACY
As yet, no medical therapy has proven effective in
reducing progression of AS or improving clinical
outcomes in patients with this condition. However, as
our understanding of the complex pathophysiological
processes underlying AS improves, novel therapeutic
strategies have been developed and are under active
investigation. A challenge is to identify patients in
whom the progressive cycle of calciﬁcation may be
reversible with effective therapy, and this may be
more likely to occur early in stages of calcium for-
mation. Most randomized trials to date have targeted
patients with mild or moderate AS, and it has been
suggested that patients would be more effectively
treated at an earlier stage. However, as the majority
of patients with aortic sclerosis do not develop AS,
identifying patients at an earlier stage who are likely
to derive beneﬁt from treatment would be chal-
lenging. Furthermore, many patients do not present
until they have developed advanced disease and so
developing therapies that halt disease progression inthis patient group is also of great importance.
Regardless of the stage of disease, it appears probable
that calciﬁcation is more likely to be reversible in its
earlier stages of development, meaning that imaging
techniques that can identify early developing calciﬁ-
cation, such as 18F-NaF PET, are likely to be of value
(Table 1).
LIPID-LOWERING STRATEGIES. Although statin
therapy has failed to slow disease progression in 3
randomized trials (73–75), the question remains as to
whether alternative lipid-lowering approaches could
be successful. One promising therapeutic target is
lipoprotein(a) [Lp(a)], a cholesterol-rich plasma
lipoprotein containing a low-density lipoprotein
particle with apolipoprotein B100 bound to apolipo-
protein A (76). Lp(a) has been recognized as a
powerful cardiovascular risk factor (76), and a recent
genome-wide association study has implicated a
single-nucleotide polymorphism in the Lp(a) locus to
the development of the disease (77).
The growing evidence that Lp(a) plays a causal role
in the development and also perhaps the progression
of AS (78,79) has led to great enthusiasm in exploring
this as a therapeutic target. One potential therapeutic
agent is niacin, which has been shown to lower Lp(a)
in a dose-dependent manner. Whether extended-
release niacin can reduce the progression of aortic
TABLE 1 Current Trials Investigating the Effects of Novel Therapies on Progression of AS
Trial Name NCT # Therapy Population Imaging Endpoints Primary Outcome
EAVall (Early Aortic Valve
Lipoprotein(a) Lowering)
NCT02109614 Niacin vs. placebo 238 participants with aortic
sclerosis or mild AS
CT calcium score
Echo
Change in CT calcium score
at 2 yrs
SALTIRE-II (Study Investigating the
Effect of Drugs Used to Treat
Osteoporosis on the Progression
of Calciﬁc Aortic Stenosis)
NCT02132026 Alendronate or
denosumab vs.
placebo
150 patients with AV Vmax
>2.5 m/s and grade 2–4
calciﬁcation on echo
CT calcium score
Echo
18F-NaF PET-CT
Change in CT calcium score
at 2 yrs
PCSK9 Inhibitors in the Progression
of Aortic Stenosis
NCT03051360 PCSK9 inhibitor vs.
placebo
140 patients with mild to
moderate AS
CT calcium score
Echo
18F-NaF PET-CT
Change in calcium score and
18F-NaF PET activity at
2 yrs
BASIK2 (Bicuspid Aortic Valve
Stenosis and the Effect of
Vitamin K2 on Calcium
Metabolism on 18F-NaF PET/
MRI)
NCT02917525 Vitamin K2 vs. placebo 44 patients with a bicuspid AV
and mild to moderate
calciﬁcation on echo
CT calcium score
Echo
18F-NaF PET-MRI
Change in 18F-NaF PET
activity at 6 months
CALCIFICA (Value of Oral Phytate
[InsP6] in the Prevention of
Progression of Cardiovascular
Calciﬁcations)
NCT01000233 Phytate vs. placebo 250 patients with grade 2 or 3
AV calciﬁcation on echo
CT calcium score CT calcium score at 2 yrs
ASPEN (Aortic Stenosis and
Phosphodiesterase Type 5
Inhibition)
NCT01275339 Tadalaﬁl vs. placebo With moderate to severe AS
(AVA <1.5 cm)
MRI
Echo
Change in LV mass at
6 months
Change in diastolic function
on echo
Change in LV longitudinal
strain on echo
CAVS (A Study Evaluating the
Effects of Ataciguat [HMR1766]
on Aortic Valve Calciﬁcation)
NCT02481258 Ataciguat (HMR1766) vs.
placebo
35 patients with AVA between
1 and 2 cm2 and calcium
score >300 AU þ EF
>50%.
CT calcium score
Echo
Change in CT calcium score
at 6 and 12 months
A summary of current trials employing imaging endpoints to assess the effects of novel therapies by utilizing imaging endpoints.
AS ¼ aortic stenosis; AU ¼ arbitrary unit(s); AV ¼ aortic valve; AVA ¼ aortic valve area; CT ¼ computed tomography; echo ¼ echocardiography; EF ¼ ejection fraction; 18F-NaF ¼ radiolabeled sodium
ﬂuoride; LV ¼ left ventricular; MRI ¼ magnetic resonance imaging; NCT ¼ national clinical trial; PCSK9 ¼ proprotein convertase subtilisin/kexin type 9; PET ¼ positron emission tomography; Vmax ¼
maximum volume.
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194valve disease is currently under investigation as part
of the EAVall (Early Aortic Valve Lipoprotein(a)
Lowering Trial) (NCT02109614). This pilot study will
randomize over 200 patients with elevated Lp(a) and
mild aortic valve disease to extended-release niacin
or placebo with a primary outcome of change in CT-
AVC at 2 years (79).
ANTICALCIFIC THERAPIES. Calciﬁcation is a key
target for novel therapies in AS given its central role
in driving progressive valvular obstruction. An
important concern, however, is how best to reduce
calciﬁcation activity in the valve while maintaining
bone health in elderly patients with AS who are at risk
of osteoporosis and fractures. One potential option is
to use treatments licensed for osteoporosis, such as
bisphosphonates or receptor activator of nuclear
factor kappa-B ligand (RANKL)-inhibitors, which not
only improve bone health but have also demonstrated
the ability to reduce vascular calciﬁcation (80). In
addition to reducing bone resorption and thereby
reducing circulating calcium and phosphate,
bisphosphonates have been shown to reduce local
production of inﬂammatory cytokines, inhibit release
of matrix metalloproteinases, and stimulatemacrophage apoptosis (81,82). Preclinical studies
have demonstrated that bisphosphonate therapy re-
duces valvular calciﬁcation in animal models (83,84).
The monoclonal antibody to RANKL, denosumab, acts
by preventing the interaction between RANKL and
RANK, a cytokine that plays an important role in up-
regulating pro-osteogenic mediators and inducing
osteoblastic transformation of valve interstitial cells.
Whether these therapies reduce the progression of
valvular calciﬁcation has yet to be determined and is
currently being investigated in the randomized
placebo-controlled trial SALTIRE II (Study Investi-
gating the Effects of Drugs Used to Treat Osteoporosis
on the Progression of Calciﬁc Aortic Stenosis)
(NCT02132026). This blinded study is using change in
CT calcium score at 2 years as the primary efﬁcacy
endpoint. However, measures of calciﬁcation activity
by PET-CT will also be performed at baseline and 1
year, in addition to serial echocardiography every 6
months (85).
Another potential anticalciﬁc therapy under inves-
tigation is vitamin K. Vitamin K is required for acti-
vation of matrix Gla protein (MGP), a potent inhibitor
of vascular calciﬁcation synthesized by vascular
smooth muscle cells. In the aortic valve, MGP acts by
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195blocking the binding of bone morphogenetic protein 2
to its receptor, thereby preventing bone morphoge-
netic protein–mediated differentiation of valve inter-
stitial cells to pro-osteogenic cells. MGP also inhibits
growth of microcalciﬁcation crystals by binding
directly to hydroxyapatite and stabilizing circulating
calcifying protein particles (86). Reduced expression
of MGP has been demonstrated in calciﬁc aortic valves
(87). The BASIK2 (Bicuspid Aortic Valve Stenosis and
the Effect of Vitamin K2 on Calcium Metabolism on
18F-NaF PET/MRI) randomized trial (NCT02917525)
will investigate the effect of vitamin K2 in 44 patients
with bicuspid aortic valve disease. The primary
outcome of the study is the change in 18F-ﬂuoride PET
signal on PET-MRI at 6 months (86).
ANTIFIBROTIC STRATEGIES. Therapies targeting the
remodeling response of the LV have also been of
interest. Whereas the RIAS trial of angiotensin-
converting enzyme–inhibitor therapy showed a
small positive effect on LV mass, a small and un-
derpowered study did not demonstrate an effect of
eplerenone on LV mass progression (88). Further
work in this ﬁeld is required particularly to investi-
gate the effects of novel therapies on myocardial
ﬁbrosis (59), with hope that more aggressive inhibi-
tion of the renin-angiotensin-aldosterone systemand or novel antiﬁbrotic therapies may prove more
effective (89–91).
CONCLUSIONS
AS represents a substantial health care burden, with
no medical therapies currently available to intervene
and halt disease progression in either the valve or
myocardium. However, advances in our understand-
ing of the complex pathophysiological basis of this
disease have led to exciting new avenues in exploring
potential therapies. Investigating the effects of new
treatments requires objective markers that are both
repeatable and sensitive to changes. Although echo-
cardiographic measures are used widely to guide
clinical practice, alternative imaging modalities such
as CT calcium scoring, CMR, and 18F-ﬂuoride PET
imaging are being used to assess disease activity and
progression in the research arena and as efﬁcacy
endpoints in ongoing trials of novel therapies.
ADDRESS FOR CORRESPONDENCE: Dr. Marc R.
Dweck, British Heart Foundation Centre for Cardio-
vascular Science, University of Edinburgh, 49 Little
France Crescent, Edinburgh, Scotland EH16 4SB,
United Kingdom. E-mail: Marc.dweck@ed.ac.uk.RE F E RENCE S1. Iung B, Baron G, Butchart EG, et al.
A prospective survey of patients with valvular
heart disease in Europe: the Euro Heart Survey on
Valvular Heart Disease. Eur Heart J 2003;24:
1231–43.
2. Nkomo VT, Gardin JM, Skelton TN,
Gottdiener JS, Scott CG, Enriquez-Sarano M.
Burden of valvular heart diseases: a population-
based study. Lancet 2006;368:1005–11.
3. Marquis-Gravel G, Redfors B, Leon MB,
Généreux P. Medical treatment of aortic stenosis.
Circulation 2016;134:1766–84.
4. Pawade TA, Newby DE, Dweck MR. Calciﬁcation
in aortic stenosis: the skeleton key. J Am Coll
Cardiol 2015;66:561–77.
5. Dweck MR, Boon NA, Newby DE. Calciﬁc aortic
stenosis: a disease of the valve and the myocar-
dium. J Am Coll Cardiol 2012;60:1854–63.
6. Kaden JJ, Dempﬂe C-E, Grobholz R, et al. In-
ﬂammatory regulation of extracellular matrix
remodeling in calciﬁc aortic valve stenosis. Car-
diovasc Pathol 2005;14:80–7.
7. Rajamannan NM. Bicuspid aortic valve disease:
the role of oxidative stress in Lrp5 bone formation.
Cardiovasc Pathol 2011;20:168–76.
8. Freeman RV, Otto CM. Spectrum of calciﬁc
aortic valve disease: pathogenesis, diseaseprogression, and treatment strategies. Circulation
2005;111:3316–26.
9. Olsson M, Dalsgaard CJ, Haegerstrand A,
Rosenqvist M, Rydén L, Nilsson J. Accumulation of
T lymphocytes and expression of interleukin-2
receptors in nonrheumatic stenotic aortic valves.
J Am Coll Cardiol 1994;23:1162–70.
10. Olsson M, Thyberg J, Nilsson J. Presence of
oxidized low density lipoprotein in nonrheumatic
stenotic aortic valves. Arterioscler Thromb Vasc
Biol 1999;19:1218–22.
11. Min H, Morony S, Sarosi I, et al. Osteoprote-
gerin reverses osteoporosis by inhibiting endosteal
osteoclasts and prevents vascular calciﬁcation by
blocking a process resembling osteoclastogenesis.
J Exp Med 2000;192:463–74.
12. Kaden JJ, Bickelhaupt S, Grobholz R, et al.
Receptor activator of nuclear factor kappaB ligand
and osteoprotegerin regulate aortic valve calciﬁ-
cation. J Mol Cell Cardiol 2004;36:57–66.
13. Dweck MR, Pawade TA, Newby DE. Aortic
stenosis begets aortic stenosis: between a rock
and a hard place? Heart 2015;101:919–20.
14. Schultz JEJ, Witt SA, Glascock BJ, et al. TGF-
beta1 mediates the hypertrophic cardiomyocyte
growth induced by angiotensin II. J Clin Invest
2002;109:787–96.15. Hein S, Arnon E, Kostin S, et al. Progression
from compensated hypertrophy to failure in the
pressure-overloaded human heart: structural
deterioration and compensatory mechanisms. Cir-
culation 2003;107:984–91.
16. Heymans S, Schroen B, Vermeersch P, et al.
Increased cardiac expression of tissue inhibitor of
metalloproteinase-1 and tissue inhibitor of
metalloproteinase-2 is related to cardiac ﬁbrosis
and dysfunction in the chronic pressure-overloaded
human heart. Circulation 2005;112:1136–44.
17. Brubakk AO, Angelsen BA, Hatle L. Diagnosis
of valvular heart disease using transcutaneous
Doppler ultrasound. Cardiovasc Res 1977;11:461–9.
18. Hatle L, Angelsen BA, Tromsdal A. Non-inva-
sive assessment of aortic stenosis by Doppler ul-
trasound. Br Heart J 1980;43:284–92.
19. Hatle L. Noninvasive assessment of valve le-
sions with Doppler ultrasound. Herz 1984;9:
213–21.
20. Holen J, Aaslid R, Landmark K, Simonsen S.
Determination of pressure gradient in mitral ste-
nosis with a non-invasive ultrasound Doppler
technique. Acta Med Scand 1976;199:455–60.
21. Otto CM, Burwash IG, Legget ME, et al. Pro-
spective study of asymptomatic valvular aortic
stenosis: clinical, echocardiographic, and exercise
Doris et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 2 , N O . 1 , 2 0 1 9
Measuring Disease Progression and Assessing Novel Therapies in AS J A N U A R Y 2 0 1 9 : 1 8 5 – 9 7
196predictors of outcome. Circulation 1997;95:
2262–70.
22. Leon MB, Smith CR, Mack M, et al., for the
PARTNER Trial Investigators. Transcatheter aortic-
valve implantation for aortic stenosis in patients
who cannot undergo surgery. N Engl J Med 2010;
363:1597–607.
23. Baumgartner H, Falk V, Bax JJ, et al., for the
ESC Scientiﬁc Document Group. 2017 ESC/EACTS
guidelines for the management of valvular heart
disease. Eur Heart J 2017;38:2739–91.
24. Rusinaru D, Malaquin D, Maréchaux S,
Debry N, Tribouilloy C. Relation of dimensionless
index to long-term outcome in aortic stenosis with
preserved LVEF. J Am Coll Cardiol Img 2015;8:
766–75.
25. Bohbot Y, Kowalski C, Rusinaru D, Ringle A,
Maréchaux S, Tribouilloy C. Impact of mean
transaortic pressure gradient on long-term
outcome in patients with severe aortic stenosis
and preserved left ventricular ejection fraction.
J Am Heart Assoc 2017;6:e005850.
26. Otto CM, Pearlman AS, Comess KA,
Reamer RP, Janko CL, Huntsman LL. Determina-
tion of the stenotic aortic valve area in adults
using Doppler echocardiography. J Am Coll Cardiol
1986;7:509–17.
27. Sacchi S, Dhutia NM, Shun-Shin MJ, et al.
Doppler assessment of aortic stenosis: a 25-
operator study demonstrating why reading the
peak velocity is superior to velocity time integral.
Eur Heart J Cardiovasc Imaging 2018;19:1380–9.
28. Moura LM, Ramos SF, Pinto FJ, Barros IM,
Rocha-Gonçalves F. Analysis of variability and
reproducibility of echocardiography measure-
ments in valvular aortic valve stenosis. Rev Port
Cardiol 2011;30:25–33.
29. Galderisi M, Henein MY, D’hooge J, et al.
Recommendations of the European Association of
Echocardiography: how to use echo-Doppler in
clinical trials: different modalities for different
purposes. Eur J Echocardiogr 2011;12:339–53.
30. Otto CM, Pearlman AS, Gardner CL. Hemody-
namic progression of aortic stenosis in adults
assessed by Doppler echocardiography. J Am Coll
Cardiol 1989;13:545–50.
31. Clavel M-A, Messika-Zeitoun D, Pibarot P,
et al. The complex nature of discordant severe
calciﬁed aortic valve disease grading: new insights
from combined Doppler echocardiographic and
computed tomographic study. J Am Coll Cardiol
2013;62:2329–38.
32. Pawade T, Clavel M-A, Tribouilloy C, et al.
Computed tomography aortic valve calcium
scoring in patients with aortic stenosis. Circ Car-
diovasc Imaging 2018;11:e007146.
33. Annabi M-S, Touboul E, Dahou A, et al.
Dobutamine stress echocardiography for man-
agement of low-ﬂow, low-gradient aortic steno-
sis. J Am Coll Cardiol 2018;71:475–85.
34. Monin JL, Monchi M, Gest V, Duval-
Moulin AM, Dubois-Rande JL, Gueret P. Aortic
stenosis with severe left ventricular dysfunction
and low transvalvular pressure gradients: risk
stratiﬁcation by low-dose dobutamine echocardi-
ography. J Am Coll Cardiol 2001;37:2101–7.35. Rosenhek R, Binder T, Porenta G, et al. Pre-
dictors of outcome in severe, asymptomatic aortic
stenosis. N Engl J Med 2000;343:611–7.
36. Rosenhek R, Klaar U, Schemper M, et al. Mild
and moderate aortic stenosis: natural history and
risk stratiﬁcation by echocardiography. Eur Heart J
2004;25:199–205.
37. Messika-Zeitoun D, Aubry M-C, Detaint D,
et al. Evaluation and clinical implications of aortic
valve calciﬁcation measured by electron-beam
computed tomography. Circulation 2004;110:
356–62.
38. Cueff C, Serfaty J-M, Cimadevilla C, et al.
Measurement of aortic valve calciﬁcation using
multislice computed tomography: correlation with
haemodynamic severity of aortic stenosis and
clinical implication for patients with low ejection
fraction. Heart 2011;97:721–6.
39. Aggarwal SR, Clavel M-A, Messika-Zeitoun D,
et al. Sex differences in aortic valve calciﬁcation
measured by multidetector computed tomography
in aortic stenosis. Circ Cardiovasc Imaging 2013;6:
40–7.
40. Tastet L, Enriquez-Sarano M, Capoulade R,
et al. Impact of aortic valve calciﬁcation and sex
on hemodynamic progression and clinical out-
comes in AS. J Am Coll Cardiol 2017;69:2096–8.
41. Morgan-Hughes GJ, Owens PE,
Roobottom CA, Marshall AJ. Three dimensional
volume quantiﬁcation of aortic valve calciﬁcation
using multislice computed tomography. Heart
2003;89:1191–4.
42. Derlin T, Richter U, Bannas P, et al. Feasibility
of 18F-sodium ﬂuoride PET/CT for imaging of
atherosclerotic plaque. J Nucl Med 2010;51:
862–5.
43. Joshi NV, Vesey AT, Williams MC, et al. 18F-
ﬂuoride positron emission tomography for identi-
ﬁcation of ruptured and high-risk coronary
atherosclerotic plaques: a prospective clinical trial.
Lancet 2014;383:705–13.
44. Irkle A, Vesey AT, Lewis DY, et al. Identifying
active vascular microcalciﬁcation by (18)F-sodium
ﬂuoride positron emission tomography. Nat Com-
mun 2015;6:7495.
45. Dweck MR, Jenkins WS, Vesey AT, et al. 18F-
sodium ﬂuoride uptake is a marker of active
calciﬁcation and disease progression in patients
with aortic stenosis. Circ Cardiovasc Imaging 2014;
7:371–8.
46. Jenkins WS, Vesey AT, Shah AS, et al. Valvular
(18)F-ﬂuoride and (18)F-ﬂuorodeoxyglucose up-
take predict disease progression and clinical
outcome in patients with aortic stenosis. J Am Coll
Cardiol 2015;66:1200–1.
47. Pawade TA, Cartlidge TR, Jenkins WS, et al.
Optimization and reproducibility of aortic valve
18F-ﬂuoride positron emission tomography in pa-
tients with aortic stenosis. Circ Cardiovasc Imaging
2016;9:e005131.
48. Installé J, Nzeusseu A, Bol A, Depresseux G,
Devogelaer J-P, Lonneux M. (18)F-ﬂuoride PET for
monitoring therapeutic response in Paget’s disease
of bone. J Nucl Med 2005;46:1650–8.49. Robson PM, Dey D, Newby DE, et al. MR/PET
imaging of the cardiovascular system. J Am Coll
Cardiol Img 2017;10:1165–79.
50. Ciofﬁ G, Faggiano P, Vizzardi E, et al. Prog-
nostic effect of inappropriately high left ventric-
ular mass in asymptomatic severe aortic stenosis.
Heart 2011;97:301–7.
51. Chin CWL, Everett RJ, Kwiecinski J, et al.
Myocardial ﬁbrosis and cardiac decompensation in
aortic stenosis. J Am Coll Cardiol Img 2017;10:
1320–33.
52. Dweck MR, Joshi S, Murigu T, et al. Midwall
ﬁbrosis is an independent predictor of mortality in
patients with aortic stenosis. J Am Coll Cardiol
2011;58:1271–9.
53. Everett RJ, Tastet L, Clavel M-A, et al. Pro-
gression of hypertrophy and myocardial ﬁbrosis in
aortic stenosis: a multicenter cardiac magnetic
resonance study. Circ Cardiovasc Imaging 2018;11:
e007451.
54. Delgado V, Tops LF, van Bommel RJ, et al.
Strain analysis in patients with severe aortic ste-
nosis and preserved left ventricular ejection frac-
tion undergoing surgical valve replacement. Eur
Heart J 2009;30:3037–47.
55. Kempny A, Diller G-P, Kaleschke G, et al.
Longitudinal left ventricular 2D strain is superior
to ejection fraction in predicting myocardial re-
covery and symptomatic improvement after aortic
valve implantation. Int J Cardiol 2013;167:
2239–43.
56. Myerson SG, Bellenger NG, Pennell DJ.
Assessment of left ventricular mass by cardiovas-
cular magnetic resonance. Hypertension 2002;39:
750–5.
57. Bellenger NG, Davies LC, Francis JM, Coats AJ,
Pennell DJ. Reduction in sample size for studies of
remodeling in heart failure by the use of cardio-
vascular magnetic resonance. J Cardiovasc Magn
Reson 2000;2:271–8.
58. Grothues F, Smith GC, Moon JC, et al. Com-
parison of interstudy reproducibility of cardiovas-
cular magnetic resonance with two-dimensional
echocardiography in normal subjects and in pa-
tients with heart failure or left ventricular hyper-
trophy. Am J Cardiol 2002;90:29–34.
59. Bull S, Loudon M, Francis JM, et al.
A prospective, double-blind, randomized
controlled trial of the angiotensin-converting
enzyme inhibitor Ramipril In Aortic Stenosis
(RIAS trial). Eur Heart J Cardiovasc Imaging 2015;
16:834–41.
60. Rudolph A, Abdel-Aty H, Bohl S, et al. Nonin-
vasive detection of ﬁbrosis applying contrast-
enhanced cardiac magnetic resonance in different
forms of left ventricular hypertrophy relation to
remodeling. J Am Coll Cardiol 2009;53:284–91.
61. Barone-Rochette G, Piérard S, De Meester de
Ravenstein C, et al. Prognostic signiﬁcance of LGE
by CMR in aortic stenosis patients undergoing
valve replacement. J Am Coll Cardiol 2014;64:
144–54.
62. de Haan S, Meijers TA, Knaapen P, Beek AM,
van Rossum AC, Allaart CP. Scar size and charac-
teristics assessed by CMR predict ventricular
arrhythmias in ischaemic cardiomyopathy:
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 2 , N O . 1 , 2 0 1 9 Doris et al.
J A N U A R Y 2 0 1 9 : 1 8 5 – 9 7 Measuring Disease Progression and Assessing Novel Therapies in AS
197comparison of previously validated models. Heart
2011;97:1951–6.
63. Schmidt A, Azevedo CF, Cheng A, et al. Infarct
tissue heterogeneity by magnetic resonance im-
aging identiﬁes enhanced cardiac arrhythmia sus-
ceptibility in patients with left ventricular
dysfunction. Circulation 2007;115:2006–14.
64. Azevedo CF, Nigri M, Higuchi ML, et al.
Prognostic signiﬁcance of myocardial ﬁbrosis
quantiﬁcation by histopathology and magnetic
resonance imaging in patients with severe aortic
valve disease. J Am Coll Cardiol 2010;56:278–87.
65. Weidemann F, Herrmann S, Störk S, et al.
Impact of myocardial ﬁbrosis in patients with
symptomatic severe aortic stenosis. Circulation
2009;120:577–84.
66. Singh A, Horsﬁeld MA, Bekele S, Khan JN,
Greiser A, McCann GP. Myocardial T1 and extracel-
lular volume fractionmeasurement in asymptomatic
patients with aortic stenosis: reproducibility and
comparison with age-matched controls. Eur Heart J
Cardiovasc Imaging 2015;16:763–70.
67. Lee H, Park J-B, Yoon YE, et al. Noncontrast
myocardial T1 mapping by cardiac magnetic reso-
nance predicts outcome in patients with aortic
stenosis. J Am Coll Cardiol Img 2018;11:974–83.
68. Chin CW, Semple S, Malley T, et al. Optimi-
zation and comparison of myocardial T1 tech-
niques at 3T in patients with aortic stenosis. Eur
Heart J Cardiovasc Imaging 2014;15:556–65.
69. Flett AS, Hayward MP, Ashworth MT, et al.
Equilibrium contrast cardiovascular magnetic
resonance for the measurement of diffuse
myocardial ﬁbrosis: preliminary validation in
humans. Circulation 2010;122:138–44.
70. Fontana M, White SK, Banypersad SM, et al.
Comparison of T1 mapping techniques for ECV
quantiﬁcation: histological validation and repro-
ducibility of ShMOLLI versus multibreath-hold T1
quantiﬁcation equilibrium contrast CMR.
J Cardiovasc Magn Reson 2012;14:88.
71. White SK, SadoDM, FontanaM, et al. T1mapping
formyocardial extracellular volumemeasurementby
CMR: bolus only versus primed infusion technique.
J Am Coll Cardiol Img 2013;6:955–62.
72. Treibel TA, Kozor R, Schoﬁeld R, et al. Reverse
myocardial remodeling following valve replacementin patients with aortic stenosis. J Am Coll Cardiol
2018;71:860–71.
73. Cowell SJ, Newby DE, Prescott RJ, et al., for
the SALTIRE Investigators. A randomized trial of
intensive lipid-lowering therapy in calciﬁc aortic
stenosis. N Engl J Med 2005;352:2389–97.
74. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J,
ASTRONOMER Investigators. Effect of lipid
lowering with rosuvastatin on progression of
aortic stenosis: results of the aortic stenosis pro-
gression observation: measuring effects of rosu-
vastatin (ASTRONOMER) trial. Circulation 2010;
121:306–14.
75. Rossebø AB, Pedersen TR, Boman K, et al., for
the SEAS Investigators. Intensive lipid lowering
with simvastatin and ezetimibe in aortic stenosis.
N Engl J Med 2008;359:1343–56.
76. Nordestgaard BG, Chapman MJ, Ray K, et al.,
for the European Atherosclerosis Society
Consensus Panel. Lipoprotein(a) as a cardiovas-
cular risk factor: current status. Eur Heart J 2010;
31:2844–53.
77. Thanassoulis G, Campbell CY, Owens DS, et al.,
for the CHARGE Extracoronary Calcium Working
Group. Genetic associations with valvular calciﬁ-
cation and aortic stenosis. N Engl J Med 2013;368:
503–12.
78. Capoulade R, Chan KL, Yeang C, et al. Oxidized
phospholipids, lipoprotein(a), and progression of
calciﬁc aortic valve stenosis. J Am Coll Cardiol
2015;66:1236–46.
79. Thanassoulis G. Lipoprotein (a) in calciﬁc
aortic valve disease: from genomics to novel drug
target for aortic stenosis. J Lipid Res 2016;57:
917–24.
80. Helas S, Goettsch C, Schoppet M, et al. Inhi-
bition of receptor activator of NF-kappaB ligand
by denosumab attenuates vascular calcium depo-
sition in mice. Am J Pathol 2009;175:473–8.
81. Lai T-J, Hsu S-F, Li T-M, et al. Alendronate
inhibits cell invasion and MMP-2 secretion in
human chondrosarcoma cell line. Acta Pharmacol
Sin 2007;28:1231–5.
82. Corrado A, Santoro N, Cantatore FP. Extra-
skeletal effects of bisphosphonates. Joint Bone
Spine 2007;74:32–8.83. Price PA, Faus SA, Williamson MK.
Bisphosphonates alendronate and ibandronate
inhibit artery calciﬁcation at doses comparable to
those that inhibit bone resorption. Arterioscler
Thromb Vasc Biol 2001;21:817–24.
84. Synetos A, Toutouzas K, Benetos G, et al.
Catheter based inhibition of arterial calciﬁcation
by bisphosphonates in an experimental athero-
sclerotic rabbit animal model. Int J Cardiol 2014;
176:177–81.
85. Clinicaltrials.gov. Study Investigating the
Effect of Drugs Used to Treat Osteoporosis on
the Progression of Calciﬁc Aortic Stenosis.
(SALTIRE II). Available at: https://clinicaltrials.
gov/ct2/show/NCT02132026. Accessed
December 4, 2018.
86. Peeters FECM, van Mourik MJW, Meex SJR,
et al. Bicuspid aortic valve stenosis and the effect
of vitamin K2 on calciﬁcation using 18F-sodium
ﬂuoride positron emission tomography/magnetic
resonance: the BASIK2 Rationale and Trial Design.
Nutrients 2018;10:E386.
87. Venardos N, Bennett D, Weyant MJ, Reece TB,
Meng X, Fullerton DA. Matrix Gla protein regulates
calciﬁcation of the aortic valve. J Surg Res 2015;
199:1–6.
88. Stewart RA, Kerr AJ, Cowan BR, et al., for the
ZEST Investigators. A randomized trial of the
aldosterone-receptor antagonist eplerenone in
asymptomatic moderate-severe aortic stenosis.
Am Heart J 2008;156:348–55.
89. Capoulade R, Clavel M-A, Mathieu P, et al.
Impact of hypertension and renin-angiotensin
system inhibitors in aortic stenosis. Eur J Clin
Invest 2013;43:1262–72.
90. Côté N, Couture C, Pibarot P, Després J-P,
Mathieu P. Angiotensin receptor blockers are
associated with a lower remodelling score of ste-
notic aortic valves. Eur J Clin Invest 2011;41:
1172–9.
91. McVicker BL, Bennett RG. Novel anti-ﬁbrotic
therapies. Front Pharmacol 2017;8:318.KEY WORDS aortic stenosis, disease
progression, noninvasive imaging, novel
therapies
